Highlights

  • Artrya’s Salix platform has entered clinical use at Northeast Georgia Health System, becoming the company’s second live US customer.
  • The deployment has begun generating revenue through monthly subscription fees and fee-per-scan charges.
  • Salix Coronary Anatomy and Salix Coronary Plaque are now being used within routine clinical workflows.
  • The first launch covers one facility, with expansion across the broader Northeast Georgia Health System network planned.
  • Artrya continues targeting commercial activation across all three of its US foundation partners.

Artrya Limited (ASX: AYA) reached another commercialisation milestone on 23 July 2026 after confirming that its Salix artificial-intelligence platform had gone live at Northeast Georgia Health System in the United States.

The deployment represents Artrya’s second live US customer and marks the start of revenue generation from the arrangement. The company said the first patient scans had been processed, with income now being earned through a monthly software subscription and fees linked to scan volumes.

Artrya shares closed at AUD 5.75 on 23 July 2026, gaining 6.28%. The S&P/ASX 200 finished 0.18% higher at 8,839.00.

What Artrya Announced

Artrya confirmed that Salix had been integrated into Northeast Georgia Health System and was operating clinically at the first location within the network.

The deployment is being delivered through Georgia Heart Institute, which Artrya describes as one of Georgia’s largest cardiology programmes and a provider serving more than 100,000 patients annually.

Salix is now being incorporated into routine diagnostic workflows involving coronary computed tomography angiography, commonly known as CCTA.

The technology analyses medical images to help clinicians identify and assess coronary artery disease, including the presence and extent of plaque within a patient’s arteries.

The company plans to extend the technology beyond the first site to additional hospitals and outpatient facilities within the health system.

Why the Go-Live Is Commercially Important

The announcement is more than a technical integration milestone because it begins revenue generation.

Technology companies in the healthcare sector often move through several stages before producing commercial revenue, including product development, regulatory clearance, clinical validation, contracting, integration and staff training.

Artrya has now moved the Northeast Georgia Health System deployment into active clinical use, with patient scans being processed and fees beginning to accrue.

This transition provides evidence that Salix can be incorporated into a large health system’s daily operations rather than remaining in a testing or evaluation phase.

However, the financial importance of the contract will depend on adoption rates, scan volumes and the speed of the broader network rollout.

How Artrya Generates Revenue From Salix

Two Salix modules are currently operating at Northeast Georgia Health System.

Salix Coronary Anatomy is provided through a monthly software-as-a-service subscription. This creates a recurring revenue stream that is not directly dependent on the number of scans completed in a particular month.

Salix Coronary Plaque uses a fee-per-scan model. Revenue from this module should therefore increase or decrease depending on clinical usage and the number of eligible CCTA scans processed.

The combination gives Artrya two types of income: a recurring subscription component and a usage-linked component.

This model may provide a degree of revenue visibility through subscriptions while allowing income to scale if doctors use the plaque-analysis technology more frequently.

A third product, Salix Coronary Flow, is not yet active in the United States because it remains subject to US Food and Drug Administration clearance.

What the Salix Platform Does

Salix is designed to analyse CCTA imaging used in the assessment of patients with suspected coronary artery disease.

The platform applies artificial intelligence to identify the anatomy of coronary arteries and assess plaque characteristics. Artrya positions the technology as a clinical decision-support tool that may help physicians evaluate chest-pain patients more efficiently.

Coronary artery disease is commonly assessed through a combination of imaging, clinical observations and further testing.

Artrya argues that more detailed AI-assisted analysis may help clinicians make faster, evidence-based decisions and potentially reduce unnecessary follow-up procedures for some patients.

The technology does not replace the treating physician. Instead, it provides additional information that doctors may use alongside their clinical judgement and other patient data.

Why Northeast Georgia Health System Matters

The scale of the customer makes the deployment relevant to Artrya’s commercial strategy.

Georgia Heart Institute reportedly serves more than 100,000 patients annually, providing a substantial clinical environment in which usage of Salix could develop.

The immediate launch covers the first facility rather than the entire Northeast Georgia Health System network. As a result, current revenue may remain modest while the rollout is in its early stages.

Expansion to additional hospitals and outpatient centres could increase the number of doctors using the system and the volume of eligible scans.

The project may also provide Artrya with operational evidence that can be used when seeking further customers in the US healthcare market.

Progress Across the US Foundation Partners

Northeast Georgia Health System is the second US customer to move into live commercial use.

Artrya has previously referred to three US foundation partners and said it remains on track to make all three commercial.

Management indicated that Cone Health is expected to follow in the near term.

Foundation partners are important because they allow an early-stage healthcare technology company to demonstrate product integration, clinical adoption and commercial viability within established health systems.

Successful deployments may help Artrya build reference sites and reduce perceived implementation risk for prospective customers.

Nevertheless, each healthcare system may have different technology, procurement, training and clinical requirements. Success at one location does not guarantee that subsequent deployments will progress at the same speed.

Regulatory Position and Product Expansion

Regulatory clearance remains central to Artrya’s product strategy.

The company has previously stated that Salix Central USA received FDA clearance under reference K243038. In Australia, Salix Coronary Anatomy is listed on the Australian Register of Therapeutic Goods.

The Coronary Flow module remains subject to FDA approval before it can be introduced into routine clinical use in the United States.

Securing clearance would broaden the capabilities available to customers and could create an additional revenue opportunity.

However, regulatory review processes are outside the company’s direct control. The timing and outcome cannot be guaranteed, and any delay could affect Artrya’s product roadmap.

Potential Growth Drivers

The first potential driver is expansion across the remaining Northeast Georgia Health System sites.

A broader rollout could increase subscription coverage, clinical users and fee-generating scan volumes.

The second is the expected commercial launch at Cone Health. Activating another foundation partner would further demonstrate Artrya’s ability to implement the platform across different US health systems.

The third is greater clinical adoption at existing customers. Under the fee-per-scan model, revenue may grow as more doctors use the system and more eligible scans are processed.

Regulatory clearance for Salix Coronary Flow could provide another driver by adding functionality and potentially increasing the commercial value of the overall platform.

New customer contracts beyond the existing foundation partners would represent a further step towards building a broader US revenue base.

Material Risks and Uncertainties

The deployment remains at an early commercial stage.

Although revenue has commenced, Artrya has not provided detailed guidance on the amount expected from Northeast Georgia Health System. Initial revenue may be limited until the platform is adopted across more facilities and scan volumes increase.

Clinical adoption is another risk. Hospitals may install new technology without immediately generating high levels of routine usage, particularly where physicians require additional training or workflow changes.

The company also faces execution risk as it manages multiple customer deployments and seeks to expand its US presence.

Artrya operates in a competitive medical-imaging and healthcare AI market where larger businesses may have greater financial, clinical or distribution resources.

As an early-commercial technology company, Artrya may also require continued investment in product development, sales, regulatory work and customer support before reaching sustained profitability.

What Investors May Monitor Next

The next important indicators will be the pace of the rollout across Northeast Georgia Health System and the number of scans processed through Salix.

Investors may also monitor confirmation that Cone Health has entered commercial use and whether the third US foundation partner progresses as planned.

Future financial reporting should provide greater visibility into subscription revenue, per-scan income and the overall contribution from US customers.

An update on the FDA review of Salix Coronary Flow would also be relevant because clearance would allow the company to offer a broader range of clinical tools.

Additional customer agreements would help demonstrate whether the foundation-partner model can translate into a repeatable commercial pipeline.

Conclusion

Artrya’s Salix platform is now operating clinically at Northeast Georgia Health System, marking the company’s second live US customer and the start of revenue from the deployment.

The commercial model combines a monthly subscription for Salix Coronary Anatomy with fee-per-scan revenue from Salix Coronary Plaque.

The deployment through Georgia Heart Institute provides access to a sizeable clinical network, although the rollout currently covers only the first site and remains at an early stage.

Progress at Cone Health, expansion across the remaining Northeast Georgia Health System facilities and evidence of growing scan volumes will help determine whether the initial deployment develops into meaningful recurring revenue.

The announcement represents measurable commercial progress, but the longer-term outcome will depend on clinical adoption, regulatory execution and Artrya’s ability to convert additional US health systems into active customers.